These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
465 related articles for article (PubMed ID: 18974239)
1. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function. Richir MC; Bouwman RH; Teerlink T; Siroen MP; de Vries TP; van Leeuwen PA JPEN J Parenter Enteral Nutr; 2008; 32(6):613-21. PubMed ID: 18974239 [TBL] [Abstract][Full Text] [Related]
2. The clinical significance of asymmetric dimethylarginine. Siroen MP; Teerlink T; Nijveldt RJ; Prins HA; Richir MC; van Leeuwen PA Annu Rev Nutr; 2006; 26():203-28. PubMed ID: 16848705 [TBL] [Abstract][Full Text] [Related]
3. The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature. Visser M; Paulus WJ; Vermeulen MA; Richir MC; Davids M; Wisselink W; de Mol BA; van Leeuwen PA Eur J Heart Fail; 2010 Dec; 12(12):1274-81. PubMed ID: 20923854 [TBL] [Abstract][Full Text] [Related]
4. Homocysteine increases the production of asymmetric dimethylarginine in cultured neurons. Selley ML J Neurosci Res; 2004 Jul; 77(1):90-3. PubMed ID: 15197741 [TBL] [Abstract][Full Text] [Related]
5. Asymmetric dimethylarginine (ADMA): the silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule. Fliser D Eur J Clin Invest; 2005 Feb; 35(2):71-9. PubMed ID: 15667575 [TBL] [Abstract][Full Text] [Related]
6. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes. Yamagishi S; Ueda S; Okuda S Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960 [TBL] [Abstract][Full Text] [Related]
7. Dimethylarginine dimethylaminohydrolase (DDAH)--a critical regulator of hypertensive left ventricular hypertrophy? Bai Y; Hui R Med Hypotheses; 2008; 70(5):962-6. PubMed ID: 17983707 [TBL] [Abstract][Full Text] [Related]
8. Liver plays a central role in asymmetric dimethylarginine-mediated organ injury. Ferrigno A; Di Pasqua LG; Berardo C; Richelmi P; Vairetti M World J Gastroenterol; 2015 May; 21(17):5131-7. PubMed ID: 25954086 [TBL] [Abstract][Full Text] [Related]
9. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor. Böger RH J Nutr; 2004 Oct; 134(10 Suppl):2842S-2847S; discussion 2853S. PubMed ID: 15465797 [TBL] [Abstract][Full Text] [Related]
10. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Böger RH Cardiovasc Res; 2003 Oct; 59(4):824-33. PubMed ID: 14553822 [TBL] [Abstract][Full Text] [Related]
11. Asymmetric dimethylarginine in children with homocystinuria or phenylketonuria. Kanzelmeyer N; Tsikas D; Chobanyan-Jürgens K; Beckmann B; Vaske B; Illsinger S; Das AM; Lücke T Amino Acids; 2012 May; 42(5):1765-72. PubMed ID: 21472412 [TBL] [Abstract][Full Text] [Related]
13. GC-MS assay for hepatic DDAH activity in diabetic and non-diabetic rats by measuring dimethylamine (DMA) formed from asymmetric dimethylarginine (ADMA): evaluation of the importance of S-nitrosothiols as inhibitors of DDAH activity in vitro and in vivo in humans. Chobanyan K; Thum T; Suchy MT; Zhu B; Mitschke A; Gutzki FM; Beckmann B; Stichtenoth DO; Tsikas D J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct; 858(1-2):32-41. PubMed ID: 17825631 [TBL] [Abstract][Full Text] [Related]
14. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule. De Gennaro Colonna V; Bianchi M; Pascale V; Ferrario P; Morelli F; Pascale W; Tomasoni L; Turiel M Med Sci Monit; 2009 Apr; 15(4):RA91-101. PubMed ID: 19333216 [TBL] [Abstract][Full Text] [Related]
15. Role of dimethylarginine dimethylaminohydrolase activity in regulation of tissue and plasma concentrations of asymmetric dimethylarginine in an animal model of prolonged critical illness. Davids M; Richir MC; Visser M; Ellger B; van den Berghe G; van Leeuwen PA; Teerlink T Metabolism; 2012 Apr; 61(4):482-90. PubMed ID: 22000584 [TBL] [Abstract][Full Text] [Related]
17. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Murray-Rust J; Leiper J; McAlister M; Phelan J; Tilley S; Santa Maria J; Vallance P; McDonald N Nat Struct Biol; 2001 Aug; 8(8):679-83. PubMed ID: 11473257 [TBL] [Abstract][Full Text] [Related]
18. Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism. Wilcken DE; Sim AS; Wang J; Wang XL Mol Genet Metab; 2007 Aug; 91(4):309-17; discussion 308. PubMed ID: 17560156 [TBL] [Abstract][Full Text] [Related]
19. Gene transfer of dimethylarginine dimethylaminohydrolase-2 improves the impairments of DDAH/ADMA/NOS/NO pathway in endothelial cells induced by lysophosphatidylcholine. Feng M; Liu L; Guo Z; Xiong Y Eur J Pharmacol; 2008 Apr; 584(1):49-56. PubMed ID: 18342305 [TBL] [Abstract][Full Text] [Related]
20. Asymmetric dimethylarginine and critical illness. Brinkmann SJ; de Boer MC; Buijs N; van Leeuwen PA Curr Opin Clin Nutr Metab Care; 2014 Jan; 17(1):90-7. PubMed ID: 24281375 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]